Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
CORRECTION — Innventure announces strategic investment in Accelsius by Johnson Controls
This press release was corrected to specify that Innventure’s private placement was…
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Amid a shifting global economy, the China…
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global…
Johnson & Johnson Launches VARIPULSE Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Acceleware Announces Board Appointments
CALGARY, Alberta, June 03, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or…